Eisai Co., Ltd. - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 181 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Eisai Co., Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Eisai Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Eisai Co., Ltd.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Eisai Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Eisai Co., Ltd.
- The report provides overview of Eisai Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Eisai Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Eisai Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Eisai Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Eisai Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eisai Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Eisai Co., Ltd. Snapshot 6
Eisai Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Eisai Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Eisai Co., Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 18
Eisai Co., Ltd. - Pipeline Products Glance 20
Eisai Co., Ltd. - Late Stage Pipeline Products 20
Eisai Co., Ltd. - Clinical Stage Pipeline Products 23
Eisai Co., Ltd. - Early Stage Pipeline Products 26
Eisai Co., Ltd. - Drug Profiles 29
donepezil hydrochloride 29
eribulin mesylate 30
lenvatinib mesylate 36
lorcaserin hydrochloride 43
mitiglinide 47
perampanel 49
clevudine 52
mecobalamin 54
avatrombopag 55
fosravuconazole 57
lemborexant 59
BAN-2401 61
denileukin diftitox 63
E-2609 66
E-3710 67
E-7820 69
indisulam 70
Vaccine for Metastatic Melanoma 72
E-6011 73
E-6201 74
E-7449 76
golvatinib + lenvatinib 77
golvatinib tartrate 79
tazemetostat 81
donepezil hydrochloride Patch 83
E-2027 85
E-7046 86
E-7090 87
E-7389LF 88
SJ-733 89
AT-791 90
E-2072 91
E-2508 92
E-5539 93
E-6446 94
ER-358063 95
ER-410660 96
ER-886046 97
ER-901356 98
Small Molecule for Epilepsy 99
Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders 100
Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders 101
Small Molecule to Inhibit Cytidine Deaminase for Oncology 102
Small Molecule to Inhibit GWT1 Protein for Malaria 103
E-209 104
Small Molecules for Bacterial Infections 105
Small Molecules for Chagas Disease 106
Small Molecules for Lymphatic Filariasis and Onchocerciasis 107
Small Molecules for Malaria 108
Small Molecules for Oncology 109
Small Molecules for Tuberculosis 110
TRI-4 111
Eisai Co., Ltd. - Pipeline Analysis 112
Eisai Co., Ltd. - Pipeline Products by Target 112
Eisai Co., Ltd. - Pipeline Products by Route of Administration 119
Eisai Co., Ltd. - Pipeline Products by Molecule Type 120
Eisai Co., Ltd. - Pipeline Products by Mechanism of Action 121
Eisai Co., Ltd. - Recent Pipeline Updates 128
Eisai Co., Ltd. - Dormant Projects 164
Eisai Co., Ltd. - Discontinued Pipeline Products 166
Discontinued Pipeline Product Profiles 166
Eisai Co., Ltd. - Company Statement 171
Eisai Co., Ltd. - Locations And Subsidiaries 172
Head Office 172
Other Locations & Subsidiaries 172
Appendix 176
Methodology 176
Coverage 176
Secondary Research 176
Primary Research 176
Expert Panel Validation 176
Contact Us 176
Disclaimer 177

List of Tables

Eisai Co., Ltd., Key Information 10
Eisai Co., Ltd., Key Facts 10
Eisai Co., Ltd. - Pipeline by Indication, 2016 12
Eisai Co., Ltd. - Pipeline by Stage of Development, 2016 17
Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2016 18
Eisai Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 19
Eisai Co., Ltd. - Partnered Products in Pipeline, 2016 20
Eisai Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 21
Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2016 22
Eisai Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 23
Eisai Co., Ltd. - Pre-Registration, 2016 24
Eisai Co., Ltd. - Filing rejected/Withdrawn, 2016 25
Eisai Co., Ltd. - Phase III, 2016 26
Eisai Co., Ltd. - Phase II, 2016 27
Eisai Co., Ltd. - Phase I, 2016 28
Eisai Co., Ltd. - Preclinical, 2016 30
Eisai Co., Ltd. - Discovery, 2016 32
Eisai Co., Ltd. - Pipeline by Target, 2016 117
Eisai Co., Ltd. - Pipeline by Route of Administration, 2016 123
Eisai Co., Ltd. - Pipeline by Molecule Type, 2016 124
Eisai Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 125
Eisai Co., Ltd. - Recent Pipeline Updates, 2016 132
Eisai Co., Ltd. - Dormant Developmental Projects,2016 168
Eisai Co., Ltd. - Discontinued Pipeline Products, 2016 170
Eisai Co., Ltd., Subsidiaries 176